{"entity":{"id":"hifi-pan-cancer-screening","kind":"drug","name":"HIFI Pan-Cancer Screening (Berry Oncology)","aka":[],"tldr":"Berry Oncology's blood test for six cancers common in China, launched in 2022; its accuracy figures are the company's own and no peer-reviewed multi-cancer paper was found.","summary":"Berry Oncology, of Beijing, announced on 23 June 2022 the launch of HIFI Pan-Cancer Screening, a one-time screening product for lung, oesophageal, gastric, liver, pancreatic and colorectal cancer, which it describes as the first multi-cancer screening product built on whole-genome sequencing of cell-free DNA. Its figures, first given in a company release of 13 October 2021 without sample sizes, are 87.6% sensitivity, 99.1% specificity and tissue of origin correct in 82% of positive cancers, with 69.6% sensitivity at stage I and 92.9% at stage II. These are company statements: no peer-reviewed paper reporting them was found (Berry Oncology's published cell-free DNA work found by this census is on single cancers: liver, pancreatic, oesophageal and nasopharyngeal). No NMPA registration, current availability or price was found.","status":"emerging","asOf":"2026-11-03","links":[{"label":"Berry Oncology: research results on multi-cancer screening (13 October 2021)","url":"https://kyodonewsprwire.jp/release/202110141615"},{"label":"Berry Oncology launch release, as reprinted (23 June 2022)","url":"https://www.1stoncology.com/blog/?p=75600"}],"tags":["test","mced","evidence:insufficient"],"related":[],"cancers":["lung-cancer","esophageal","gastric","hcc","pancreatic","colorectal"],"sections":[],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":[],"companies":["berry-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.","Every accuracy figure is the company's, from releases without cohort sizes.","What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening)."],"brand":"HIFI","modality":"Multi-cancer early detection blood test (whole-genome sequencing of cell-free DNA)","mechanism":"Whole-genome sequencing of cell-free DNA (Berry Oncology's HIFI method) read by machine learning, with a predicted tissue of origin.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/hifi-pan-cancer-screening/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"company":[{"id":"berry-oncology","kind":"company","name":"Berry Oncology","route":"/companies/berry-oncology/"}]}}